GlassScriptPhysician profile
Jeffrey A Jackman
NPI 1437111622
$1,970.40
in general payments reported to CMS, 2019-2025
23 companies · $291 in 2025
The $291 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $759 · 2020: $127 · 2022: $24.81 · 2023: $445 · 2024: $324 · 2025: $291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,060.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,059.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $427.86 | 2019-2025 | |
| Amgen INC. | $340.20 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $206.42 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $151.05 | 2019-2025 | Camzyos |
| Sanofi-Aventis U.S. LLC | $141.95 | 2019-2020 | |
| Pfizer INC. | $122.30 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.99 | 2019-2024 | Jardiance |
| Amarin Pharma, INC. | $77.06 | 2019 | |
| Boston Scientific Corporation | $51.54 | 2023 | Watchman Access System |
| Regeneron Healthcare Solutions, INC. | $50.44 | 2019 | |
| Recor Medical INC | $34.55 | 2025 | Paradise Ultrasound Renal Denervation System |
| Merck Sharp & Dohme LLC | $34.15 | 2023 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $33.31 | 2023-2025 | Brilinta, Farxiga |
| Tactile Systems Technology INC | $29.48 | 2023 | Flexitouch Plus, Entre Plus |
| Lilly USA, LLC | $28.97 | 2025 | Zepbound |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $25.30 | 2024 | Arcalyst |
| Scpharmaceuticals INC. | $24.40 | 2025 | |
| Abbott Laboratories | $22.43 | 2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Novo Nordisk INC | $22.19 | 2023 | Rybelsus, Ozempic |
| Vital Connect, INC | $21.48 | 2023 | Vitalpatch Rtm |
| Kowa Pharmaceuticals America, INC. | $16.43 | 2019 | |
| Arbor Pharmaceuticals, INC. | $15.54 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.36 | 2025 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Jackman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.